Medical Device Industry News June 8, 2026 | FDA, PMDA, M&A Trends

In the medical device industry from June 1st to June 7th, 2026, there was notable activity related to surgical assistance robots, structural heart disease, diabetes devices, sleep and neurostimulation devices, and SaMD.

In the United States, major medical device manufacturers such as Medtronic, Edwards, Dexcom, and ResMed advanced their product development and M&A activities. Meanwhile, in Japan, the PMDA published review points for home-use program medical devices, drawing attention to review practices in the digital health and SaMD sectors.

This article summarizes the main medical device news from the first week of June 2026, organized from the perspective of regulatory affairs and PMDA applications.

This Week's Top News

1. Medtronic Submits 510(k) for Hugo Robotic-Assisted Surgery System for Expanded Indications

On June 3, 2026, Medtronic announced that it has submitted a 510(k) application for its Hugo robotic-assisted surgery system to expand its indications for use in general surgery and gynecology in the United States.

Hugo has already received FDA clearance for urological procedures in the U.S. If this application is approved, it could broaden competition in key surgical areas where Intuitive Surgical's da Vinci has a strong presence in the robotic-assisted surgery market.

The company also announced that it has a 510(k) application pending for the LigaSure RAS Maryland instrument for the Hugo RAS system, and that it has obtained 510(k) clearance for its ProGrip Advanced self-gripping polypropylene mesh.

2. Edwards' Surgical Tricuspid Valve "TRIFORMIS RESILIA" Gains Renewed Attention

In the first week of June 2026, several industry media outlets reported news related to the FDA approval of Edwards Lifesciences' surgical tricuspid valve replacement, "TRIFORMIS RESILIA Tricuspid Valve."

In the FDA's PMA database, the product can be found as PMA Supplement P150048/S092. The approval allows for the existing MITRIS RESILIA Mitral Valve to have its indication expanded to the tricuspid position, with the modified product being marketed as "TRIFORMIS RESILIA Tricuspid Valve."

It should be noted that the Decision Date in the FDA database is October 27, 2025, meaning it was not newly approved in June 2026. For a weekly news summary, it is appropriate to categorize this as a topic that received renewed coverage by industry media in the first week of June.

This product's evaluation also utilized real-world data where the existing mitral valve product was used in the tricuspid position, making it a notable case study for leveraging existing technology and data for new indications.

3. FDA Updates Policy on 510(k) Exemptions for Certain Unclassified Medical Devices

In June 2026, the FDA updated its guidance indicating its intent to exempt certain unclassified medical devices from 510(k) submission requirements.

This guidance states that the FDA believes the devices in question meet the criteria for 510(k) exemption and, until a formal exemption is issued, the agency will generally not enforce 510(k) requirements for them.

In the United States, there is an ongoing trend to reduce the burden of premarket review for low-risk devices. However, in Japan, FDA's 510(k) exemption does not directly correspond to notification or certification requirements. Therefore, when selling in Japan, it is necessary to separately confirm the JMDN, classification, and the existence of certification standards.

4. Dexcom Announces Acquisition Agreement with Nutrisense and Expansion of CGM Utilization

On June 4, 2026, Dexcom announced the signing of an agreement to acquire Nutrisense, a company that develops wellness applications leveraging CGM data. The acquisition is expected to close within a few weeks, subject to customary closing conditions and regulatory approvals.

Nutrisense offers a service that combines CGM data with nutritional guidance to provide personalized support for behavioral change. With this acquisition, Dexcom indicates its strategy to expand CGM use beyond diabetes management into early intervention, prevention, and wellness sectors.

Furthermore, at ADA 2026, results from the CONNECT randomized controlled trial, which evaluated the use of Dexcom CGM in insulin-naïve adults with type 2 diabetes, were also presented. These findings are attracting attention as evidence that expands the clinical utility of CGM into earlier intervention areas.

5. MiniMed Expands Collaboration with Abbott

MiniMed, a spin-off from Medtronic, has announced its intention to expand its collaboration with Abbott to develop a dual glucose-ketone sensor.

The new dual monitoring sensor aims for early and real-time detection of elevated ketones, which can help prevent diabetic ketoacidosis (DKA).

In the diabetes device sector, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, algorithms, apps, and cloud connectivity are increasingly integrating. This makes it crucial to evaluate the entire system rather than individual devices.

6. ResMed Completes Acquisition of Noctrix Health

ResMed announced on June 1, 2026, the completion of its acquisition of Noctrix Health for $340 million.

Noctrix Health is a company that develops Nidra, a non-invasive neurostimulation device for Restless Legs Syndrome (RLS). With this acquisition, ResMed aims to expand its portfolio into the clinical sleep health sector, including RLS, in addition to its traditional sleep apnea domain.

In the sleep sector, treatment systems are expanding to combine respiratory support devices like CPAP with neurostimulation, wearables, and digital monitoring.

7. CereVasc Raises $85 Million in Series C Funding

CereVasc has secured $85 million in Series C funding to advance the development of its "eShunt," a minimally invasive treatment device for normal pressure hydrocephalus.

Investors include Johnson & Johnson's venture investment arm and Medtronic. The funds are earmarked for ongoing pivotal trials and regulatory affairs.

The eShunt is a device designed to address challenges associated with traditional ventriculoperitoneal shunts by utilizing a minimally invasive endovascular approach via femoral vein access.

8. Olympus's Gastrointestinal Endoscopy Robotics Strategy Gains Renewed Attention

Among the industry trends in the first week of June, Olympus's gastrointestinal endoscopy robotics strategy also received renewed attention. On June 5, 2026, MedTech Dive highlighted the company's endoluminal robotics strategy through an interview with the head of Olympus's gastrointestinal solutions division.

Olympus, a company with a strong product foundation in the gastrointestinal endoscopy field, is expanding into the robotics domain to support endoscopic treatments through collaborations with Swan EndoSurgical and EndoRobotics.

In gastrointestinal endoscopy robotics, unlike conventional treatment instruments, functions such as operational assistance, forceps manipulation, lesion resection, suturing, hemostasis, and traction are integrated. When applying for approval of similar devices in Japan in the future, key considerations will include not only equivalence to existing instruments but also operability, usability, endoscope compatibility, and the necessity of clinical evaluation.

9. PMDA Publishes Review Points for Home-Use Programmed Medical Devices

On June 5, 2026, the PMDA published "Review Points for Home-Use Programmed Medical Devices that Detect Signs of Disease and Encourage Medical Consultation."

These review points specifically target home-use programmed medical devices that detect signs of disease and encourage medical consultation, using vital data and other information collected via sensors from general-purpose digital devices not originally distributed as medical devices, such as smartphones, smartwatches, and high-performance earphones, as input.

Unlike programs intended for medical institutions, home-use SaMD (Software as a Medical Device) is designed for use by general consumers. Therefore, display content, recommendations for medical consultation, false positives/negatives, usability, and risk communication become crucial considerations.

Perspectives on the Japanese Market and PMDA Applications

Looking at this week's news, medical device product development is accelerating in the US through FDA approvals, 510(k) clearances, De Novo classifications, M&A, and funding rounds.

However, even products with FDA approval or 510(k) clearance cannot be sold in Japan as-is. For entry into the Japanese market, the following points must be individually addressed:

Generic Name (JMDN)
Class Classification
Existence of Certification Standards
Applicability of Approval, Certification, or Notification
Application Category (New Medical Device, Improved Medical Device, Generic Medical Device)
Necessity of Clinical Evaluation Data
Extrapolation Possibility of Overseas Clinical Data
QMS Conformity Assessment
DMAH or Marketing Authorization Holder System
Possibility of Insurance Coverage

Especially for surgical support robots, SaMD, neurostimulation devices, long-term implantable devices, and gastrointestinal endoscopes, it is crucial to consider not only overseas approval data but also the differences from existing approved products in Japan, clinical evaluation, and how to proceed with PMDA consultations.

Summary

In the first week of June 2026, news related to surgical assistance robots, structural heart disease, diabetes devices, sleep and neurostimulation devices, gastrointestinal endoscopy robotics, and SaMD was prominent.

Overseas, there is a trend towards expanding the application of existing technologies, extending CGM into preventive and wellness domains, acquiring neurostimulation devices, and investing in minimally invasive devices. In Japan, PMDA has published review points for home-use program medical devices, further solidifying the practical review procedures for the SaMD field.

When overseas manufacturers enter the Japanese market, a comprehensive regulatory strategy is required. This strategy should encompass not only FDA approval or 510(k) status, but also the application route under Japan's Pharmaceutical and Medical Device Act (PMD Act), clinical evaluation, PMDA consultations, QMS, and health insurance listing.

MK Consulting provides support for market entry into Japan, focusing on gastrointestinal endoscopy devices, biliary-pancreatic devices, and medical devices where clinical evaluation is crucial. Our services include regulatory strategy, PMDA consultations, CER/STED creation, and assistance in selecting DMAH candidates.